



Press release July 10, 2013

New clinical study with Tigran™ PTG verifies bone formation (osteoconduction)

In a clinical study in a microCT and histological evaluation of biopsy specimens from 17 patients participating in a clinical trial on sinus lift using Tigran's non-resorbable Porous Titanium Granules (PTG), researchers have verified bone formation, mainly woven bone in close contact with the surface of the granules and bridging the intergranular space. No signs of inflammation in any of the biopsy specimens were observed. The authors point out that a prerequisite for sinus lift is primary implant stability and they underline that a significant resorption of a bone graft may occur over time, which may compromise the long-term implant stability. The authors conclude that the porous structure of PTG may favor osteoconduction and contribute to the stability that is necessary for long-term implant survival. The study has been published in the June issue of the International Journal of Oral & Maxillofacial Implants.

Verket A, Lyngstadaas SP, Rasmusson L, Haanæs HR, Wallstrom M, Wall G, Wohlfahrt JC. Maxillary sinus augmentation with porous titanium granules: a microcomputed tomography and histologic evaluation of human biopsy specimens. Int J Oral Maxillofac Implants 2013;28(3):721-8

Arve Nilsson, acting CEO and director of Tigran Technologies, said: "With 17 patients, this is a relatively large study. I am very pleased with the results in terms of bone growth but also with the authors comments on the all-important primary stability."

For further information, please contact:

Arve Nilsson, acting CEO
Tigran Technologies
+46 768 60 77 10
a.nilsson@tigran.se
www.tigran.se

About Tigran Technologies

Tigran Technologies AB (publ) is a dental development company based in Sweden. With its products Tigran™ PTG, Tigran™ PTG White and Tigran™ PeriBrush™, Tigran contributes to modern and effective treatment methods for dental clinicians and better treatment results for patients.

Tigran runs an extensive development program and has several published, submitted and on-going experimental and clinical studies. Its products are CE marked and covered by a comprehensive patent portfolio.

'Tigran' is a registered trademark.

Tigran Technologies AB (publ) is since November 2008 listed on AktieTorget.

